Other AbbVie drugs, including its once-best-selling multiuse medication Humira, have been targeted by new provisions in the ...

Under the agreement, Neomorph will receive an undisclosed upfront payment from AbbVie and be eligible for up to $1.64 billion in aggregate option fees and milestones.

AbbVie (NYSE: ABBV) announced today that it has completed its acquisition of Nimble Therapeutics. With the completion of the acquisition, Nimble is now a part of AbbVie.

AbbVie (ABBV – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Tim Anderson from Bank of ...

In response to growing demand for personalized, patient-centric aesthetic solutions1,2, Allergan Aesthetics, an AbbVie Company, is proud to unveil the new AA Signature program, an innovative approach ...

In a report released today, Christopher Raymond from Piper Sandler maintained a Buy rating on AbbVie (ABBV – Research Report), with a price ...

Chicago-based drug major AbbVie and privately-held San Diego firm Neomorph have announced a collaboration and option-to-license agreement to develop novel molecular glue degraders for multiple targets ...

screening and optimization platform to strengthen AbbVie's pipeline and R&D capabilities NORTH CHICAGO, Ill., Jan. 23, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) announced today that it has ...

NORTH CHICAGO, Ill. - AbbVie (NYSE: NYSE:ABBV), a global biopharmaceutical company with a market capitalization of $299 billion and annual revenue exceeding $55 billion, has announced the completion ...

NORTH CHICAGO, Ill. - AbbVie (NYSE: NYSE:ABBV), a prominent player in the biotechnology industry with a market capitalization of $299 billion, and Neomorph, Inc. have entered into a collaboration to ...

*AA Signature, by Allergan Aesthetics, is a new program that is launching Internationally at the IMCAS congress in Paris and will be considered for roll out across International markets, as ...